BioLynx
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- Undisclosed
Investors
- 6
About BioLynx
, trading as BioLynx, operates as a biotechnology company that focuses on developing in vitro diagnostic reagents and antibody. In 2016, the company established a scientific antibody research and development and production base. In 2020, it acquired EU CE certification. The company's main products include LYNX310 equipment, immunochromogenic systems and auxiliary reagents, and RUO reagents. The LYNX310 device provides full-process services from baking to counterstaining in immunohistochemistry experiments. The company’s revenue is generated by providing antibody screening solutions.
Who invested in BioLynx
6 investors across 3 rounds
See all investors in BioLynx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BioLynx
Who invested in BioLynx?
BioLynx has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioLynx raised?
BioLynx has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did BioLynx last raise money?
BioLynx's most recent round on record is a Series A, in Mar 2021.
What does BioLynx do?
, trading as BioLynx, operates as a biotechnology company that focuses on developing in vitro diagnostic reagents and antibody.
Where is BioLynx headquartered?
BioLynx is headquartered in Hangzhou, China.
Which VCs invest in companies like BioLynx?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BioLynx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BioLynx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.